Four things to know:
1. Dr. Scopp is director of the joint preservation center at POC.
2. The study’s goal is to compare the efficacy of the Agili-C cartilage regeneration implant to the current standard of care — microfracture and debridement.
3. POC is one of 15 U.S. clinical facilities participating in the investigational device exemption study.
4. The study enrolled 241 out of 250 patients so far.
More articles on devices:
Dr. Adrian Park: Work-related injuries affecting orthopedic, spine surgeons & other specialists
Penn Medicine researchers seek to improve spinal discs’ early response to injury
Emory, Duke & more: 4 facilities participate in $13M clinical trial for knee stem cell treatment
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.